The role of thrombolytic protein therapy in the prevention of microvascular complications in non-insulin-dependent diabetes mellitus: an integrative approach

Abstract

Non-Insulin-Dependent Diabetes Mellitus (NIDDM) is associated with an increased risk of microvascular complications. Thrombolytic protein therapy may help prevent these complications, but its efficacy remains unclear. We aimed to comprehensively evaluate the role of thrombolytic protein therapy in preventing microvascular complications in NIDDM patients through an integrated analysis of bioinformatics and clinical data. A retrospective cohort study design was utilized. Bioinformatics analysis included transcriptomic profiling, single-nucleotide polymorphism identification, and predictive modeling. Clinical parameters involving patient demographics, medical history, and lab results were collected and analyzed. Transcriptomic analysis identified differentially expressed genes related to microvascular complications, including ABCA1, MMP9, VEGFA, and FN1. Pathway enrichment analysis revealed associations with blood vessel development, extracellular matrix organization, inflammation, and angiogenesis pathways. Single-nucleotide polymorphism analysis identified genetic variants associated with complications. Predictive models achieved high accuracy, sensitivity, and specificity in forecasting individual thrombolytic therapy responses. Clinical data provided insights into population characteristics and comorbidities. The results provide evidence that thrombolytic protein therapy may help prevent microvascular complications in NIDDM patients by modulating molecular pathways and genetic risks. Bioinformatics-guided predictive modeling shows promise for personalized treatment. Further research is needed to validate these findings and optimize thrombolytic protein therapy approaches.